Gsk (GSK) Notes Payables (2009 - 2026)
Gsk (GSK) posted Notes Payables of $4.0 billion for Q4 2025, up 32.36% on a QoQ basis from $3.0 billion in Q4 2024, and up 32.36% year-over-year from $3.0 billion in Q4 2024.
Gsk (GSK) has 10 years of Notes Payables data on file, last reported at $4.0 billion in Q4 2025.
- In Q4 2025, Notes Payables rose 32.36% year-over-year to $4.0 billion; the TTM figure through Dec 2025 stood at $4.0 billion (up 32.36% YoY), while the FY2025 annual figure was $4.0 billion, up 32.36% from the prior year.
- Notes Payables improved to $4.0 billion in Q4 2025, from $3.0 billion in the prior quarter.
- Across five years, Notes Payables topped out at $4.9 billion in Q4 2021 and bottomed at $3.0 billion in Q4 2024.
- A 5-year average of $4.0 billion and a median of $4.0 billion in 2025 frame the typical range for Notes Payables.
- Annual changes were most pronounced in 2023 — Notes Payables slipped 24.68% — and 2025, when it jumped 32.36%.
- Year by year, Notes Payables stood at $4.9 billion in 2021, then decreased by 4.51% to $4.6 billion in 2022, then slipped by 24.68% to $3.5 billion in 2023, then fell by 13.65% to $3.0 billion in 2024, then jumped by 32.36% to $4.0 billion in 2025.
- The last three Notes Payables figures came in at $4.0 billion (Q4 2025), $3.0 billion (Q4 2024), and $3.5 billion (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -327.61 Mn |
| Dec 31, 2025 | -4.01 Bn |
| Sep 30, 2025 | -3.85 Bn |
| Jun 30, 2025 | -2.73 Bn |
| Mar 31, 2025 | -268.27 Mn |
| Dec 31, 2024 | 3.01 Bn |
| Sep 30, 2024 | -213.09 Mn |
| Jun 30, 2024 | -4.25 Bn |
| Mar 31, 2024 | -256.24 Mn |
| Dec 31, 2023 | 3.49 Bn |
| Sep 30, 2023 | -198.87 Mn |
| Jun 30, 2023 | -7.41 Bn |
| Mar 31, 2023 | -205.42 Mn |
| Dec 31, 2022 | 4.64 Bn |
| Sep 30, 2022 | -299.35 Mn |
| Jun 30, 2022 | -4.19 Bn |
| Mar 31, 2022 | -289.84 Mn |
| Dec 31, 2021 | 4.85 Bn |
| Sep 30, 2021 | -357.05 Mn |
| Jun 30, 2021 | -7.05 Bn |
| Mar 31, 2021 | -859.07 Mn |
| Dec 31, 2020 | 4.92 Bn |
| Sep 28, 2020 | -622.90 Mn |
| Jun 30, 2020 | -7.41 Bn |
| Mar 31, 2020 | -671.70 Mn |
| Dec 31, 2019 | 8.89 Bn |
| Sep 30, 2019 | -10.13 Bn |
| Jun 30, 2019 | -13.05 Bn |
| Mar 31, 2019 | -259.07 Mn |
| Dec 31, 2018 | 7.45 Bn |
| Sep 30, 2018 | -268.51 Mn |
| Jun 30, 2018 | -4.73 Bn |
| Mar 31, 2018 | -343.59 Mn |
| Dec 31, 2017 | 3.75 Bn |
| Sep 30, 2017 | -6.20 Bn |
| Jun 30, 2017 | -8.45 Bn |
| Mar 31, 2017 | -566.11 Mn |
| Dec 31, 2016 | 5.13 Bn |
| Sep 30, 2016 | -1.27 Bn |
| Jun 30, 2016 | -6.44 Bn |
| Mar 31, 2016 | -1.73 Bn |
| Dec 31, 2015 | -1.98 Bn |
| Sep 30, 2015 | -2.55 Bn |
| Jun 30, 2015 | -4.36 Bn |
| Mar 31, 2015 | -691.61 Mn |
| Dec 31, 2014 | -4.66 Bn |
| Sep 30, 2014 | -509.84 Mn |
| Jun 30, 2014 | -5.29 Bn |
| Mar 31, 2014 | -465.00 Mn |
| Dec 31, 2013 | -4.52 Bn |
| Sep 30, 2013 | -4.27 Bn |
| Jun 30, 2013 | -3.58 Bn |
| Mar 31, 2013 | -472.61 Mn |
| Dec 31, 2012 | 364.53 Mn |
| Sep 30, 2012 | -173.71 Mn |
| Jun 30, 2012 | -5.79 Bn |
| Mar 31, 2012 | -4.28 Bn |
| Dec 31, 2011 | 202.73 Mn |
| Sep 30, 2011 | -1.40 Bn |
| Jun 30, 2011 | -1.69 Bn |
| Mar 31, 2011 | -413.15 Mn |
| Dec 31, 2010 | -394.97 Mn |
| Sep 30, 2010 | -531.82 Mn |
| Jun 30, 2010 | -676.18 Mn |
| Mar 31, 2010 | -1.61 Bn |
| Dec 31, 2009 | -2.40 Bn |
| Sep 30, 2009 | -567.72 Mn |
| Jun 30, 2009 | -1.83 Bn |
| Mar 31, 2009 | -494.32 Mn |